Avenue Therapeutics Inc. (ATXI) Financial Statements (2025 and earlier)
Company Profile
| Business Address |
1111 KANE CONCOURSE BAY HARBOR ISLANDS, FL 33154 |
| State of Incorp. | DE |
| Fiscal Year End | December 31 |
| Industry (SIC) | 2834 - Pharmaceutical Preparations (benchmarking) |
| More info | Complete Financial Analysis Financial Benchmarking |
Balance Sheet (Statement of Financial Position) (USD)
| 9/30/2024 MRQ | 12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 | 12/31/2018 | |||
|---|---|---|---|---|---|---|---|---|---|
| ASSETS | |||||||||
| Current Assets | |||||||||
| Cash, cash equivalents, and short-term investments | 1,783,000 | 6,708,000 | 3,763,000 | 3,132,000 | 8,745,000 | 2,671,000 | |||
| Cash and cash equivalents | 1,783,000 | 6,708,000 | 3,763,000 | 3,132,000 | 8,745,000 | 2,671,000 | |||
| Receivables | 90,000 | ||||||||
| Deferred costs | 1,702,000 | ||||||||
| Other undisclosed current assets | 107,000 | ||||||||
| Total current assets: | 1,783,000 | 6,708,000 | 3,960,000 | 3,132,000 | 8,745,000 | 4,373,000 | |||
| Noncurrent Assets | |||||||||
| Other undisclosed assets | 67,000 | 137,000 | 113,000 | 170,000 | 152,000 | ||||
| TOTAL ASSETS: | 1,850,000 | 6,845,000 | 3,960,000 | 3,245,000 | 8,915,000 | 4,525,000 | |||
| LIABILITIES AND EQUITY | |||||||||
| Liabilities | |||||||||
| Current Liabilities | |||||||||
| Accounts payable and accrued liabilities, including: | 287,000 | 949,000 | 451,000 | 857,000 | 1,101,000 | 4,669,000 | |||
| Employee-related liabilities | ✕ | ✕ | ✕ | 24,000 | 23,000 | 477,000 | 463,000 | ||
| Accounts payable | 78,000 | 129,000 | 304,000 | 143,000 | 354,000 | 3,089,000 | |||
| Accrued liabilities | 209,000 | 612,000 | 123,000 | 691,000 | 270,000 | 1,117,000 | |||
| Other undisclosed accounts payable and accrued liabilities | 208,000 | ||||||||
| Derivative instruments and hedges, liabilities | 586,000 | ||||||||
| Other undisclosed current liabilities | 323,000 | 2,630,000 | 58,000 | 29,000 | 1,014,000 | 487,000 | |||
| Total current liabilities: | 1,196,000 | 3,579,000 | 509,000 | 886,000 | 2,115,000 | 5,156,000 | |||
| Noncurrent Liabilities | |||||||||
| Total liabilities: | 1,196,000 | 3,579,000 | 509,000 | 886,000 | 2,115,000 | 5,156,000 | |||
| Equity | |||||||||
| Equity, attributable to parent | 1,582,000 | 3,905,000 | 3,451,000 | 2,359,000 | 6,800,000 | (631,000) | |||
| Common stock | 3,000 | 2,000 | 2,000 | 2,000 | 1,000 | ||||
| Additional paid in capital | 92,507,000 | 84,456,000 | 80,448,000 | 75,625,000 | 74,915,000 | 41,577,000 | |||
| Accumulated deficit | (90,928,000) | (80,551,000) | (76,999,000) | (73,268,000) | (68,117,000) | (42,209,000) | |||
| Equity, attributable to noncontrolling interest | (928,000) | (639,000) | |||||||
| Total equity: | 654,000 | 3,266,000 | 3,451,000 | 2,359,000 | 6,800,000 | (631,000) | |||
| TOTAL LIABILITIES AND EQUITY: | 1,850,000 | 6,845,000 | 3,960,000 | 3,245,000 | 8,915,000 | 4,525,000 | |||
Income Statement (P&L) (USD)
| 9/30/2024 TTM | 12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 | 12/31/2018 | ||
|---|---|---|---|---|---|---|---|---|
| Operating expenses | (10,310,000) | (8,043,000) | (3,738,000) | (5,213,000) | (25,265,000) | (21,816,000) | ||
| Other undisclosed operating loss | (4,230,000) | (1,000,000) | ||||||
| Operating loss: | (14,540,000) | (8,043,000) | (3,738,000) | (5,213,000) | (26,265,000) | (21,816,000) | ||
| Nonoperating income (expense) | 126,000 | 20,000 | 7,000 | 62,000 | 357,000 | 268,000 | ||
| Investment income, nonoperating | 126,000 | 20,000 | 7,000 | 62,000 | 357,000 | 93,000 | ||
| Other nonoperating income | 175,000 | |||||||
| Loss from continuing operations: | (14,414,000) | (8,023,000) | (3,731,000) | (5,151,000) | (25,908,000) | (21,548,000) | ||
| Loss before gain (loss) on sale of properties: | ✕ | ✕ | ✕ | (3,731,000) | (5,151,000) | (25,908,000) | (21,548,000) | |
| Other undisclosed net income | 3,926,000 | 4,420,000 | ||||||
| Net loss: | (10,488,000) | (3,603,000) | (3,731,000) | (5,151,000) | (25,908,000) | (21,548,000) | ||
| Net income attributable to noncontrolling interest | 111,000 | 51,000 | ||||||
| Net loss attributable to parent: | (10,377,000) | (3,552,000) | (3,731,000) | (5,151,000) | (25,908,000) | (21,548,000) | ||
| Other undisclosed net loss available to common stockholders, basic | ||||||||
| Net loss available to common stockholders, diluted: | (10,377,000) | (3,552,000) | (3,731,000) | (5,151,000) | (25,908,000) | (21,548,000) | ||
Comprehensive Income (USD)
| 9/30/2024 TTM | 12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 | 12/31/2018 | ||
|---|---|---|---|---|---|---|---|---|
| Net loss: | (10,488,000) | (3,603,000) | (3,731,000) | (5,151,000) | (25,908,000) | (21,548,000) | ||
| Comprehensive loss: | (10,488,000) | (3,603,000) | (3,731,000) | (5,151,000) | (25,908,000) | (21,548,000) | ||
| Comprehensive income, net of tax, attributable to noncontrolling interest | 111,000 | 51,000 | ||||||
| Comprehensive loss, net of tax, attributable to parent: | (10,377,000) | (3,552,000) | (3,731,000) | (5,151,000) | (25,908,000) | (21,548,000) | ||
Statements Sources
The financial statements are based on the Company's filings with the U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.